APA
Click to copy
Rando, H., Wellhausen, N., Ghosh, S., Lee, A. J., Dattoli, A. A., Hu, F., … Greene, C. (2021). Identification and Development of Therapeutics for COVID-19. ArXiv.org.
Chicago/Turabian
Click to copy
Rando, H., Nils Wellhausen, Soumita Ghosh, Alexandra J. Lee, A. A. Dattoli, Fenglin Hu, J. B. Byrd, et al. “Identification and Development of Therapeutics for COVID-19.” arXiv.org (2021).
MLA
Click to copy
Rando, H., et al. “Identification and Development of Therapeutics for COVID-19.” ArXiv.org, 2021.
BibTeX Click to copy
@article{h2021a,
title = {Identification and Development of Therapeutics for COVID-19},
year = {2021},
journal = {arXiv.org},
author = {Rando, H. and Wellhausen, Nils and Ghosh, Soumita and Lee, Alexandra J. and Dattoli, A. A. and Hu, Fenglin and Byrd, J. B. and Rafizadeh, Diane N. and Qi, Yanjun and Sun, Yuchen and Field, J. and Guebila, Marouen Ben and Jadavji, N. and Lordan, R. and Skelly, Ashwin N. and Ramsundar, Bharath and Brueffer, C. and Wang, Jinhui and Goel, R. and Park, YoSon and Consortium, COVID-19 Review and Boca, S. and Gitter, A. and Greene, C.}
}
After emerging in China in late 2019, the novel coronavirus SARS-CoV-2 spread worldwide and as of mid-2021 remains a significant threat globally. Only a few coronaviruses are known to infect humans, and only two cause infections similar in severity to SARS-CoV-2: Severe acute respiratory syndrome-related coronavirus, a closely related species of SARS-CoV-2 that emerged in 2002, and Middle East respiratory syndrome-related coronavirus, which emerged in 2012. Unlike the current pandemic, previous epidemics were controlled rapidly through public health measures, but the body of research investigating severe acute respiratory syndrome and Middle East respiratory syndrome has proven valuable for identifying approaches to treating and preventing novel coronavirus disease 2019 (COVID-19). Building on this research, the medical and scientific communities have responded rapidly to the COVID-19 crisis to identify many candidate therapeutics. The approaches used to identify candidates fall into four main categories: adaptation of clinical approaches to diseases with related pathologies, adaptation based on virological properties, adaptation based on host response, and data-driven identification of candidates based on physical properties or on pharmacological compendia. To date, a small number of therapeutics have already been authorized by regulatory agencies such as the Food and Drug Administration (FDA), while most remain under investigation. The scale of the COVID-19 crisis offers a rare opportunity to collect data on the effects of candidate therapeutics. This information provides insight not only into the management of coronavirus diseases, but also into the relative success of different approaches to identifying candidate therapeutics against an emerging disease.